Inverness Medical Innovations to Participate at Bank of America 2008 Smid Cap Conference on March 26, 2008

WALTHAM, Mass., March 18 Inverness MedicalInnovations, Inc. (Amex: IMA), a leading manufacturer and marketer of rapiddiagnostic products for the consumer and professional markets, announced todaythat it will attend the upcoming Bank of America 2008 Small and Mid (Smid) CapConference being held March 26-27, 2008 at the Four Seasons Hotel in Boston.Ron Zwanziger, Chief Executive Officer, and Jon Russell, Vice President,Finance, will attend. Their presentation is scheduled for Wednesday, March26, 2008 at 8:50 a.m., and will be made available to the public through awebcast accessible through the company's website athttp://www.invmed.com/investors.cfm, or directly through the following link:http://www.veracast.com/webcasts/bas/smidcap08/id88102208.cfm. A replay ofthe webcast will be available approximately 1 hour after the end of the liveevent through April 11, 2008. During their presentation Mr. Zwanziger and Mr.Russell may discuss and answer questions concerning business and financialdevelopments and trends. Their responses to questions, as well as othermatters discussed during the webcast, may contain or constitute informationthat has not been disclosed previously.

Prior to the conference Inverness will also be posting an updated investorpresentation to its website at http://www.invmed.com/presentations.cfm.

By developing new capabilities in near-patient diagnosis, monitoring andhealth management, Inverness Medical Innovations enables individuals to takecharge of improving their health and quality of life. A global leader inrapid point-of-care diagnostics, Inverness' products, as well as its newproduct development efforts, focus on infectious disease, cardiology,oncology, drugs of abuse and women's health. Inverness is headquartered inWaltham, Massachusetts.

SOURCE Inverness Medical Innovations, Inc.

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...